IBTA e-News May 2019 now out

By 31st May 2019 July 1st, 2019 e-News Archive
[31 May 2019] The IBTA's monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.

You can also read the IBTA e-News May 2019 edition in full online here.

Some of the highlights from this month's round-up:

  • Global biopharmaceutical company, AbbVie, has stopped enrolling patients in its Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin in newly-diagnosed glioblastoma due to lack of survival benefit.
  • Bristol-Myers Squibb has announced that their Phase 3 CheckMate-498 trial did not meet its primary endpoint of overall survival at final analysis.
  • Canada's first brain tumour registry has been launched with the aim of providing better treatment and avoiding a reliance on information from other countries.  It is hoped that this will aid research as well as accelerate advocacy efforts to ensure equal access to treatments and services for all brain tumour patients.
  • Giolan (5-aminolevulinic acid, 5-ALA), dubbed the "pink drink", has been rolled out as part of the National Health Service (NHS) Long Term Plan.  This allows neurosurgeons to more accurately see affected areas of the brain, leading to a higher percentage of successful tumour removal.
  • Published in the Journal of Clinical Oncology, results from The Children's Oncology Group ACNS0121 Phase 2 study have shown that radiation therapy given immediately after surgery to children younger than three years old with ependymoma extended the event-free survival (EFS) to levels seen in older children.
  • Scientists report in Nature that they have identified cells responsible for the development of brain tumours in children.  The researchers investigated the different types of normal brain cells and how they developed in the cerebellum at various time points.
  • Researchers have found a type of molecule called variable lymphocyte receptors (VLRs), in the immune system of the lamprey, a parasitic fish .  The researchers believe that VLRs could specifically target the disrupted BBB and potentially deliver therapies.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.